Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Biol Psychiatry ; 48(10): 996-1000, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11082474

ABSTRACT

BACKGROUND: Although pregnancy has frequently been described as a time of emotional well-being, some women experience significant antenatal depression that may require treatment with antidepressants. The purpose of this investigation was to examine the relative effects of early and late trimester exposure to fluoxetine and perinatal outcome. METHODS: Obstetric and neonatal records were reviewed for 64 mother-infant pairs where there was documented use of fluoxetine at some point during pregnancy. Differences in several measures of obstetrical outcome and neonatal well-being were examined in early trimester- and late trimester-exposed infants. RESULTS: No differences in birth weight and acute neonatal outcome were evident across the two groups, though there was a higher frequency of special care nursery admissions for infants with exposure to fluoxetine late in pregnancy. Special care nursery admissions could not be attributed to any specific factor. CONCLUSIONS: Given the growing numbers of women who are treated with antidepressants, including fluoxetine, during pregnancy, and the strong association between depression during pregnancy and risk for postpartum depression, patients may be best advised to continue treatment with antidepressants through labor and delivery versus making any change in intensity of treatment during the acute peripartum period.


Subject(s)
Antidepressive Agents, Second-Generation/adverse effects , Fluoxetine/adverse effects , Pregnancy Outcome , Adult , Antidepressive Agents, Second-Generation/pharmacokinetics , Apgar Score , Birth Weight/drug effects , Female , Fluoxetine/pharmacokinetics , Gestational Age , Humans , Infant, Newborn , Pregnancy
2.
Pediatrics ; 104(1): e11, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10390297

ABSTRACT

OBJECTIVE: The relative risk of psychotropic medication use in women with puerperal psychiatric illness who are breastfeeding has yet to be quantified adequately. Although the emotional and medical benefits of breastfeeding and adverse effects of maternal depression on infant development are well described, how these absolute benefits weigh against the potential effects of psychotropic drug use during lactation to ultimately guide clinical decisions is still unclear. The objective of this report was to evaluate the extent that psychotropic medications were present in the serum of infants breastfed by mothers treated with antidepressants and benzodiazepines. DESIGN: Serum samples were obtained from 35 nursing infants whose mothers were treated with psychotropic medications while breastfeeding. When a detectable concentration of medication was reported, information regarding infant behavior was obtained by maternal report. SETTING: The Perinatal and Reproductive Psychiatry Program at Massachusetts General Hospital serves as a regional consultation center for the treatment of psychiatric disorders during pregnancy and the postpartum period. PATIENTS: Subjects were mothers referred to the Perinatal Psychiatry Program for consultation regarding the relative safety of psychotropic medication use while breastfeeding. PRIMARY OUTCOME MEASURES: Presence of detectable levels of medication in infants whose mothers breastfed while taking psychotropic medications during pregnancy and/or during the puerperium and the well-being (based on maternal report) of infants who had detectable serum concentrations of medication. RESULTS: Seventy-four percent (n = 26) of infants had serum medication concentrations below the laboratory limit of detection (assay sensitivity 5-50 ng/mL). In the remaining 26% of the sample (n = 9), serum concentrations of psychotropic medications and/or active metabolites were detected. In each of these cases, infants had been exposed to the medication during pregnancy. Medications were not detected in infant serum when mothers had taken these agents solely during the postpartum period. No readily apparent difficulties with the infants were reported by mothers. CONCLUSIONS: These data support the low incidence of infant toxicity and adverse effects associated with antidepressant and benzodiazepine use during breastfeeding. These data also suggest that infant serum monitoring is helpful in the assessment of medication exposure in children of mothers who breastfeed while using psychotropic medications. Given the limited accumulated data regarding serum concentrations of psychotropic medications in breastfeeding infants, no single agent seems to be safer than another. Therefore, choice of pharmacologic treatment should be guided by the likelihood that it will result in restoration of maternal psychiatric well-being.


Subject(s)
Antidepressive Agents/blood , Breast Feeding , Tranquilizing Agents/blood , Benzodiazepines/blood , Female , Humans , Infant , Infant Behavior/drug effects , Male , Mental Disorders/drug therapy , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Trimester, Third , Puerperal Disorders/drug therapy
6.
Acad Psychiatry ; 16(1): 10-3, 1992 Mar.
Article in English | MEDLINE | ID: mdl-24443107

ABSTRACT

Teaching as a faculty activity is often undereinphasized in medical faculty reward systems for a variety of reasons. One method of recognizing teaching excellence has been through annual teaching awards offered by many departments and colleges. The authors surveyed department of psychiatry faculty regarding teaching awards, particularly questioning whether such awards influence teaching behavior or serve a motivational function. The results suggest such awards serve an important recognition function, but a lesser motivational function in academic psychiatry.

7.
Am J Ment Retard ; 95(1): 110-9, 1990 Jul.
Article in English | MEDLINE | ID: mdl-1974768

ABSTRACT

The psychopharmacologic treatment of persons with mental retardation who exhibit aggressive or self-injurious syndromes is varied and controversial. Many psychotropic agents (e.g., antipsychotics, benzodiazepines, lithium, psychostimulants, anticonvulsants, and narcotic antagonists) have been used; currently, none of these have been studied sufficiently to recommend them unequivocally, and most have serious potential side effects. A new group of medications, blockers of the beta-adrenergic function of the sympathetic nervous system, have been postulated to have efficacy in some aggressive or self-injurious persons. This literature was reviewed, a relevant case report presented, and concerns raised regarding premature endorsement of beta-blocking medications before they have been adequately studied.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Aggression/drug effects , Intellectual Disability/drug therapy , Self Mutilation/drug therapy , Administration, Oral , Adult , Dose-Response Relationship, Drug , Humans , Male , Propranolol/therapeutic use
8.
J Am Dent Assoc ; 98(6): 947-8, 1979 Jun.
Article in English | MEDLINE | ID: mdl-379096

ABSTRACT

A technique for repairing the anterior region with use of aluminous porcelain-bonded-to-platinum-foil has been described. This technique produces a strong replacement and maintains the esthetic appearance of the original prosthesis.


Subject(s)
Crowns , Denture Repair/methods , Dental Porcelain , Denture, Partial, Fixed , Incisor , Platinum
SELECTION OF CITATIONS
SEARCH DETAIL
...